Physician profile
Sparsh Jain
NPI 1922714864
$1,006.78
in general payments reported to CMS, 2019-2025
9 companies · $973 in 2025
The $973 reported for 2025 was more than what 77% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $33.77 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,007.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,006.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $529.70 | 2025 | Clareon, Unity, Centurion |
| Bausch & Lomb Americas INC. | $123.56 | 2025 | Stellaris, Envista Mx60 Iol, Envista Envy Iol |
| Glaukos Corporation | $110.13 | 2025 | Idosetr, Istent Infinite |
| Johnson & Johnson Surgical Vision, INC. | $74.86 | 2025 | Tecnis Iol, Tecnis Simplicity |
| Merz Pharmaceuticals, LLC | $38.88 | 2025 | Xeomin |
| Amgen INC. | $36.89 | 2025 | Tepezza |
| Ethicon US, LLC | $33.77 | 2024 | Prolene |
| Dompe US, INC. | $32.19 | 2025 | Oxervate |
| Abbvie INC. | $26.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sparsh Jain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.